contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


gabather-ab-invited-by-the-alzheimers-drug-discovery-foundation-usa-to-submit-a-grant-application-to-expand-the-studies-with-gt-002-in-preclinical-models-of-alzheimers-disease

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö. 

Gabather

Gabather has been invited by the Alzheimer's Drug Discovery Foundation (ADDF), USA to submit a research grant application to further investigate the effects of GT-002 in genetic models of Alzheimer...

<div class="abstract"><p>Gabather has been invited by the Alzheimer's Drug Discovery Foundation (ADDF), USA to submit a research grant application to further investigate the effects of GT-002 in genetic models of Alzheimer's disease. The project application is based on the preliminary data with GT-002 on restoring slow wave oscillations in an Alzheimer's disease model generated during the collaboration between Gabather and Harvard Medical School (HMS).</p></div><p>The project includes the teams from Professor Ksenia Kastanenka (HMS) and Professor Simon Schultz, Imperial Collage London, as well as Gabather as project coordinator. The efficacy of GT-002 to restore dysfunctional brain signals and cognitive functions will be studied. &nbsp;</p><p>Positive results from these studies will strengthen the case for clinical trials of GT-002 in cognitive dysfunction, particularly in Alzheimer's disease patients.</p><p>The drug candidate GT-002 is a selective GABAA receptor modulator with the potential to improve the treatment of several common psychiatric disorders. The results from the Phase 1 clinical trials show that the drug candidate is safe and well tolerated and has excellent pharmacokinetic properties in healthy individuals receiving single, as well as repeated doses of GT-002. A clinical study to explore the interaction of GT-002 with GABAA receptors and how it affects human brain activity will be initiated when the medical authority in Portugal has approved the application.</p>

Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!